Andrew Kruegel (Sames Group)
1:30pm - 2:30pm
Agonists and antagonists of opioid receptors represent a promising avenue for the development of new therapeutics effective in the treatment of mood disorders, including depression and anxiety. Chemical and pharmacological explorations of three unusual opioid modulating molecular scaffolds will be discussed: Iboga alkaloids, Mitragyna alkaloids, and tianeptine. Points of discussion will include diversity-oriented synthetic strategies, structure-activity relationships, and molecular design within each skeleton. Also described will be in vivo studies implicating opioid receptor activation in the antidepressant action of the known drug tianeptine, and mechanistic hypotheses to explain this connection.